Trial reportThe Journal of international medical research2025
Cardiac function and quality of life improvement with fasudil hydrochloride in patients with diabetes post-PCI: a randomized controlled trial.
Trial report in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe assessed the efficacy of fasudil hydrochloride, a Rho-kinase inhibitor, as adjunct therapy for enhancing cardiac function, managing blood sugar, and improving quality of life in patients with diabetes who have coronary heart disease (CHD) and who underwent percutaneous coronary intervention (PCI).
methodsWe conducted a randomized controlled trial including 100 patients with diabetes and CHD who underwent PCI. Participants were randomly assigned to an experimental group receiving fasudil hydrochloride plus standard therapy or a control group receiving standard therapy alone. Treatment outcomes were evaluated over 3 months, focusing on cardiac function, blood sugar levels, and quality of life across physical, social, activities of daily living, and psychological domains.
resultsThe experimental group showed significant improvement in cardiac function and blood sugar control, compared with the control group. Additionally, quality of life scores were markedly higher for the experimental group in all evaluated domains.
conclusionsFasudil hydrochloride effectively targets endothelial dysfunction and atherosclerosis, contributing to better cardiac performance and metabolic regulation. These effects translate into improved post-PCI quality of life for patients with diabetes and CHD. As an adjunct to standard PCI therapy, fasudil hydrochloride treatment offers a promising strategy for enhancing clinical outcomes in this high-risk patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.